Centrus's New HALEU Deal Is a Funding Deal, Not a Fuel Deal

There is a useful tell buried in Centrus Energy's (LEU) announcement this week that it signed a long-term contract to supply high-assay, low-enriched uranium (HALEU) to Radiant's Kaleidos microreactors: the press release does not disclose a dollar value or a volume. What it does state is that Centrus will begin delivering the fuel before the end of the decade, and that the agreement includes prepayments from Radiant meant to advance Centrus's build-out of domestic enrichment capacity.

That second clause is the story. For a beginner, this looks like a headline monopoly win: Centrus operates the only U.S.-origin enrichment cascade that can make HALEU, advanced reactors all need it, and now a reactor developer has locked itself in as a customer. The price action is the first crack in that narrative. The stock is down roughly a quarter since the start of the year even as the company has stacked up contract wins, and it trades far below its 52-week high. The market is not paying for today's earnings power, because there is almost none to pay for; it is paying for a build-out that does not yet generate cash.

The funding gap no press release announces

This is the part worth testing with an engineer's eyes. Centrus is not a mature cash generator; it is a company mid-construction. Trailing twelve-month free cash flow is negative by roughly $164 million, and operating cash flow is negative too, while the company funnels capital into enrichment capacity. The balance sheet is the saving grace — about $1.9 billion of cash on hand — but that war chest is what the entire expansion plan must draw down.

The scale of the plan explains why. In July, Centrus finalized the terms of a $900 million Department of Energy task order to expand HALEU production at its Piketon, Ohio plant, with options that lift the total potential value past $1 billion. The initial commercial build-out targets 12 metric tons of HALEU capacity a year, with the first new capacity expected online by 2029. Centrus has already produced more than 1,900 kilograms of HALEU cumulatively under its earlier demonstration work.

That is a lot of capability under construction, and almost none of it has converted into the kind of earnings multiples the stock's valuation assumes. The trailing price-to-earnings ratio is in the mid-70s and enterprise value sits at a huge multiple of EBITDA. When a company is priced that richly on a negative-cash-flow base, the entire thesis hinges on future revenue arriving on schedule — which is why the funding question is the only question.

Why the prepayment matters

Despite the "monopoly" label, HALEU's future is not purely a government story, and that is precisely what the Radiant deal signals. Centrus has said its expansion will be funded through a mix that includes national security missions, third-party investments — naming prepayments explicitly — and commercial contracts. Every prepayment from a reactor developer is capital Centrus does not have to raise as debt or equity, and each one is a vote of commercial demand independent of Washington.

The "unobligated" designation is the strategic detail that makes commercial and defense demand overlap rather than compete. Because Centrus's AC100 enrichment technology and its manufacturing supply chain are U.S.-origin, the fuel it sells is not tied to a single use and can serve national security deployments as well as civilian reactors. That widens the pool of customers who can credibly write prepayment checks.

But keep the size honest. No volume and no value were disclosed, deliveries do not begin until before 2030, and Radiant is itself early — moving from its first Kaleidos test toward deployment. This is a direction, not a magnitude. One more name on the backlog helps the case that commercial HALEU demand and customer-funded capacity are real; it does not tell you how much cash Centrus will actually collect, or when.

The judgment follows from the structure. The Radiant agreement is a mild positive that addresses one of the two real risks on this stock — over-reliance on federal appropriations that have frayed — by adding a second, private funding path. It does not change the other risk, which is that a company running negative cash flow carries a valuation that assumes years of flawless conversion from capacity to cash. In my opinion, the deal is evidence that Centrus's capabilities are being validated, not evidence that the economics have arrived. The condition that would change my read is disclosure of actual volumes and contract values, or financing progress that shrinks the funding gap — with the stock's valuation embedded as it is, I would want to see cash converted before paying up for the fuel's promise.